Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

planenuts444 Mar. 19 at 11:36 PM

$SNSE Sensei Biotherapeutics ( SNSE) is estimated to release its Q4 2025 earnings on Friday, March 27, 2026. How does everyone feel about this upcoming event?

0 · Reply

fasteddiecakes Mar. 18 at 1:30 PM

$UCAR lots of scred shorts here today. LOL $SNSE $EONR $BATL

0 · Reply

DARKP00L Mar. 17 at 10:22 AM

$SNSE 06:05 on Mar. 17 2026 Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule #tradeideas

0 · Reply

FoxyDreams Mar. 16 at 8:44 PM

1@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $AKAN $WOK $MVST $SNSE <<<> watching

1 · Reply

luklyz Mar. 16 at 7:19 PM

$SNSE they aquire Faeth Therapeutics and it is difficult to find any information about both companies. Here is a link to Faeth ongoing Phase 2 for the use sapaniserib https://clinicaltrials.gov/study/NCT06463028?spons=Faeth%20Therapeutics&rank=1 Big problem is that this study will not be done till 2029. The study was started in 2024. Most likely the preliminary data will be released sometime end of 2026 or early 2027.

0 · Reply

SqueezeSharkie Mar. 16 at 6:47 PM

$SNSE Before most people even woke up, I was already on it 👀📈 Follow to catch the next opportunity early ;)

0 · Reply

FastRocketTraders Mar. 16 at 6:08 PM

$SNSE 50+ soon?

0 · Reply

Buyout_offer Mar. 14 at 2:50 AM

$SNSE SNSE is Mr Miyagi approved!

1 · Reply

Shroomm Mar. 11 at 7:07 PM

$SNSE Great call, my biggest trade this year Dropped @MomentumZeus a Follow, Great trader!! Putting my profit in to $ASNS $PAVS $OCGN now lets ride

0 · Reply

OfficialStocktwitsUser Mar. 11 at 6:06 PM

$SNSE RSI: 55.08, MACD: 4.4645 Vol: 9.09, MA20: 26.27, MA50: 16.56 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 8:00 AM EST - 4 weeks ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Jan 7, 2026, 8:00 AM EST - 2 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Nov 14, 2025, 7:30 AM EST - 4 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 5 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 5 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 3 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

planenuts444 Mar. 19 at 11:36 PM

$SNSE Sensei Biotherapeutics ( SNSE) is estimated to release its Q4 2025 earnings on Friday, March 27, 2026. How does everyone feel about this upcoming event?

0 · Reply

fasteddiecakes Mar. 18 at 1:30 PM

$UCAR lots of scred shorts here today. LOL $SNSE $EONR $BATL

0 · Reply

DARKP00L Mar. 17 at 10:22 AM

$SNSE 06:05 on Mar. 17 2026 Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule #tradeideas

0 · Reply

FoxyDreams Mar. 16 at 8:44 PM

1 · Reply

luklyz Mar. 16 at 7:19 PM

0 · Reply

SqueezeSharkie Mar. 16 at 6:47 PM

$SNSE Before most people even woke up, I was already on it 👀📈 Follow to catch the next opportunity early ;)

0 · Reply

FastRocketTraders Mar. 16 at 6:08 PM

$SNSE 50+ soon?

0 · Reply

Buyout_offer Mar. 14 at 2:50 AM

$SNSE SNSE is Mr Miyagi approved!

1 · Reply

Shroomm Mar. 11 at 7:07 PM

$SNSE Great call, my biggest trade this year Dropped @MomentumZeus a Follow, Great trader!! Putting my profit in to $ASNS $PAVS $OCGN now lets ride

0 · Reply

OfficialStocktwitsUser Mar. 11 at 6:06 PM

0 · Reply

skyrockets_Inc Mar. 10 at 6:03 PM

$NEUP I expect news to happen in next 2-3 weeks MAX (by end of Q1). All the strategic alternative plays lately have been bangers...expect this to be nothing less. Still has a -30% downside risk if RM deal is TERRIBLE but given they have over 12 competing offers and already rejected a 4.75/share buyout, a bad deal is less likely IMO. $VYNE, $RLYB, $SNSE, all ended amazingly as predicted. This one should be NEXT! LFG!

0 · Reply

onjonx Mar. 10 at 2:49 PM

$IBRX any huge progress boom $30+ we can pull a $SNSE move anyday now

0 · Reply

petersadick Mar. 9 at 10:40 PM

$SNSE quite the after hours drop, probably a one share sale to drop it

0 · Reply

smartmoney43 Mar. 4 at 8:27 PM

$SNSE lets go!!!!

0 · Reply

petersadick Mar. 4 at 3:15 AM

$SNSE i am baffeled at why this was ever going for 330.00 a share to a decline after is't first 18 months down to 29.00 and then takie 3 years to get back to 29.00?

0 · Reply

Bullbear1010101 Mar. 2 at 2:52 AM

$SNSE 29.2

0 · Reply

JdNews Feb. 28 at 3:07 AM

$IBRX The biggest party on ST right now. But, seriously not slot of bios these days running with such hype. One comes to mind $SNSE . Which just hit 35. Both immunobios for cancer. This will follow them soon. 30 is doable.

1 · Reply

SqueezeSharkie Feb. 27 at 8:21 PM

$SNSE While others were sleeping, I was already on it 👀📈 Follow to catch the next opportunity before it pops.

1 · Reply

smartmoney43 Feb. 27 at 6:16 PM

$SNSE 👀

0 · Reply

kuwaitimilionaire Feb. 27 at 3:19 AM

$ALBT private pacement is good to the company its not offering look at $SNSE bfore 3 days had private at price of $13 its now $30 look at $XWEL before yesterday had private placement at price 0.3 its now 1.4 i believe $ALBT should stay above $1 to fulfil compliance as it now partnering with AMD

0 · Reply

discussionbo7 Feb. 25 at 11:09 PM

$SNSE $GCTS the next one to give me heart attack always early

2 · Reply

Market Cap	39.81M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	108,100
Avg Vol	360,360
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	62%
Beta	-0.12
Analysts	Hold
Price Target	$35.00